Hemispherx says FDA rejects fatigue drug application
Posted on February 04, 2013 at 21:22 PM EST
Feb 4 (Reuters) - Hemispherx Biopharma Inc said U.S. regulators had declined to approve its new drug application for Ampligen, its experimental drug for treating chronic fatigue syndrome, five years after the company first filed for the drug's approval.